Longitudinal analysis of cell-free mutated KRAS and CA 19-9 predicts survival following curative resection of pancreatic cancer
Abstract <jats:underline>Background:</jats:underline> Novel biomarkers and molecular monitoring tools hold potential to improve outcome for patients following resection of pancreatic ductal adenocarcinoma (PDAC). We hypothesized that the combined longitudinal analysis of mutated cell-free plasma KRAS (cfKRASmut) and CA 19-9 during adjuvant treatment and follow-up might more accurately predict disease course than hitherto available parameters. <jats:underline>Methods:</jats:underline> Between 07/2015 and 10/2018, we collected 134 plasma samples from 25 patients after R0/R1-resection of PDAC during adjuvant chemotherapy and post-treatment surveillance at our institution. Highly sensitive discriminatory multi-target ddPCR assays were employed to screen plasma samples for cfKRASmut. cfKRASmut and CA 19-9 dynamics were correlated with recurrence-free survival (RFS) and overall survival (OS). Patients were followed-up until 01/2020.<jats:underline>Results:</jats:underline> Out of 25 enrolled patients, 76% had undergone R0 resection and 48% of resected PDACs were pN0. 17/25 (68%) of patients underwent adjuvant chemotherapy. Median follow-up was 22.0 months, with 19 out of 25 (76%) patients relapsing during study period. Median RFS was 10.0 months, median OS was 22.0 months. Out of clinicopathologic variables, only postoperative CA 19-9 levels and administration of adjuvant chemotherapy correlated with survival endpoints. cfKRASmut. was detected in 12/25 (48%) of patients, and detection of high levels inversely correlated with survival endpoint. Integration of cfKRASmut and CA 19-9 levels outperformed either individual marker. cfKRASmut outperformed CA 19-9 as dynamic marker since increase during adjuvant chemotherapy and follow-up was highly predictive of early relapse and poor OS. <jats:underline>Conclusions:</jats:underline> Integrated analysis of cfKRASmut and CA 19-9 levels is a promising approach for molecular monitoring of patients following resection of PDAC. Larger prospective studies are needed to further develop this approach and dissect each marker`s specific potential..
Medienart: |
Preprint |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
ResearchSquare.com - (2022) vom: 29. Juli Zur Gesamtaufnahme - year:2022 |
---|
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Hussung, Saskia [VerfasserIn] |
---|
Links: |
---|
Themen: |
---|
doi: |
10.21203/rs.3.rs-60848/v4 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
XRA033980500 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | XRA033980500 | ||
003 | DE-627 | ||
005 | 20230429190911.0 | ||
007 | cr uuu---uuuuu | ||
008 | 220113s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.21203/rs.3.rs-60848/v4 |2 doi | |
035 | |a (DE-627)XRA033980500 | ||
035 | |a (ResearchSquare)10.21203/rs.3.rs-60848/v4 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Hussung, Saskia |e verfasserin |4 aut | |
245 | 1 | 0 | |a Longitudinal analysis of cell-free mutated KRAS and CA 19-9 predicts survival following curative resection of pancreatic cancer |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Abstract <jats:underline>Background:</jats:underline> Novel biomarkers and molecular monitoring tools hold potential to improve outcome for patients following resection of pancreatic ductal adenocarcinoma (PDAC). We hypothesized that the combined longitudinal analysis of mutated cell-free plasma KRAS (cfKRASmut) and CA 19-9 during adjuvant treatment and follow-up might more accurately predict disease course than hitherto available parameters. <jats:underline>Methods:</jats:underline> Between 07/2015 and 10/2018, we collected 134 plasma samples from 25 patients after R0/R1-resection of PDAC during adjuvant chemotherapy and post-treatment surveillance at our institution. Highly sensitive discriminatory multi-target ddPCR assays were employed to screen plasma samples for cfKRASmut. cfKRASmut and CA 19-9 dynamics were correlated with recurrence-free survival (RFS) and overall survival (OS). Patients were followed-up until 01/2020.<jats:underline>Results:</jats:underline> Out of 25 enrolled patients, 76% had undergone R0 resection and 48% of resected PDACs were pN0. 17/25 (68%) of patients underwent adjuvant chemotherapy. Median follow-up was 22.0 months, with 19 out of 25 (76%) patients relapsing during study period. Median RFS was 10.0 months, median OS was 22.0 months. Out of clinicopathologic variables, only postoperative CA 19-9 levels and administration of adjuvant chemotherapy correlated with survival endpoints. cfKRASmut. was detected in 12/25 (48%) of patients, and detection of high levels inversely correlated with survival endpoint. Integration of cfKRASmut and CA 19-9 levels outperformed either individual marker. cfKRASmut outperformed CA 19-9 as dynamic marker since increase during adjuvant chemotherapy and follow-up was highly predictive of early relapse and poor OS. <jats:underline>Conclusions:</jats:underline> Integrated analysis of cfKRASmut and CA 19-9 levels is a promising approach for molecular monitoring of patients following resection of PDAC. Larger prospective studies are needed to further develop this approach and dissect each marker`s specific potential. | ||
650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
700 | 1 | |a Akhoundova, Dilara |e verfasserin |4 aut | |
700 | 1 | |a Hipp, Julian |e verfasserin |4 aut | |
700 | 1 | |a Follo, Marie |e verfasserin |4 aut | |
700 | 1 | |a Klar, Rhena |e verfasserin |4 aut | |
700 | 1 | |a Philipp, Ulrike |e verfasserin |4 aut | |
700 | 1 | |a Scherer, Florian |e verfasserin |4 aut | |
700 | 1 | |a von Bubnoff, Nikolas |e verfasserin |4 aut | |
700 | 1 | |a Duyster, Justus |e verfasserin |4 aut | |
700 | 1 | |a Börries, Melanie |e verfasserin |4 aut | |
700 | 1 | |a Wittel, Uwe |e verfasserin |4 aut | |
700 | 1 | |a Fritsch, Ralph |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t ResearchSquare.com |g (2022) vom: 29. Juli |
773 | 1 | 8 | |g year:2022 |g day:29 |g month:07 |
856 | 4 | 0 | |u https://doi.org/10.1186/s12885-020-07736-x |z lizenzpflichtig |3 Volltext |
856 | 4 | 0 | |u http://dx.doi.org/10.21203/rs.3.rs-60848/v4 |z kostenfrei |3 Volltext |
912 | |a GBV_XRA | ||
912 | |a SSG-OLC-PHA | ||
951 | |a AR | ||
952 | |j 2022 |b 29 |c 07 |